Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits.

Nauck M, Marre M

Postgraduate medicine1 May 2009Cited by 25 (Europe PMC)

PMID19491535DOI10.3810/pgm.2009.05.1997PepBankPUB-19491535

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on prior OAD monotherapy, adding liraglutide 1.8 mg reduced HbA1c significantly more than adding rosiglitazone.
In plain wordsIn adults with type 2 diabetes, adding liraglutide lowered HbA1c more than adding rosiglitazone.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change from baseline
Study
n: not reported in source
Comparator
Rosiglitazone plus glimepiride
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
There was a significant reduction in HbA1c in patients previously treated with OAD monotherapy (P < 0.0001) and significantly more patients achieved HbA1c < 7% (P = 0.0005) with the addition of liraglutide than with rosiglitazone.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis included a subset of patients receiving prior OAD monotherapy from 2 phase 3, 26-week, randomized, double-blind, double-dummy, active-control, parallel-group, multicenter, multinational trials.
Summary · context
Patients were then randomized to liraglutide (1.8 mg, 1.2 mg, or 0.6 mg once daily), placebo (OAD monotherapy plus placebo), or active comparator (rosiglitazone or glimepiride).
Report a problemFND-1949153501
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on prior OAD monotherapy, significantly more patients reached HbA1c below 7% with added liraglutide 1.8 mg than with rosiglitazone.
In plain wordsIn adults with type 2 diabetes, more people reached the HbA1c target with liraglutide than with rosiglitazone.
Peptide
Liraglutide
Outcome
IncreasePatients reaching HbA1c below 7%
Study
n: not reported in source
Comparator
Rosiglitazone plus glimepiride
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
There was a significant reduction in HbA1c in patients previously treated with OAD monotherapy (P < 0.0001) and significantly more patients achieved HbA1c < 7% (P = 0.0005) with the addition of liraglutide than with rosiglitazone.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis included a subset of patients receiving prior OAD monotherapy from 2 phase 3, 26-week, randomized, double-blind, double-dummy, active-control, parallel-group, multicenter, multinational trials.
Summary · context
Patients were then randomized to liraglutide (1.8 mg, 1.2 mg, or 0.6 mg once daily), placebo (OAD monotherapy plus placebo), or active comparator (rosiglitazone or glimepiride).
Report a problemFND-1949153502
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on prior OAD monotherapy, rosiglitazone plus glimepiride caused significantly more weight gain than liraglutide plus glimepiride.
In plain wordsIn adults with type 2 diabetes, people gained more weight on rosiglitazone than on liraglutide.
Peptide
Liraglutide
Outcome
DecreaseWeight gain
Study
n: not reported in source
Comparator
Rosiglitazone plus glimepiride
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
In addition, rosiglitazone plus glimepiride was associated with significantly more weight gain (P < 0.0001) than liraglutide plus glimepiride (P = 0.04).
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis included a subset of patients receiving prior OAD monotherapy from 2 phase 3, 26-week, randomized, double-blind, double-dummy, active-control, parallel-group, multicenter, multinational trials.
Summary · context
Patients were then randomized to liraglutide (1.8 mg, 1.2 mg, or 0.6 mg once daily), placebo (OAD monotherapy plus placebo), or active comparator (rosiglitazone or glimepiride).
Report a problemFND-1949153503
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin monotherapy, patients given glimepiride had significantly more weight gain than those given liraglutide.
In plain wordsIn adults with type 2 diabetes on metformin, people gained more weight with glimepiride than with liraglutide.
Peptide
Liraglutide
Outcome
DecreaseWeight gain on metformin monotherapy
Study
n: not reported in source
Comparator
Glimepiride
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
For patients on metformin monotherapy, the addition of liraglutide or glimepiride resulted in similar levels of glycemic control; however, patients receiving glimepiride had significantly greater weight gain (P < 0.0001) and higher rates of minor hyperglycemia.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis included a subset of patients receiving prior OAD monotherapy from 2 phase 3, 26-week, randomized, double-blind, double-dummy, active-control, parallel-group, multicenter, multinational trials.
Summary · context
Patients were then randomized to liraglutide (1.8 mg, 1.2 mg, or 0.6 mg once daily), placebo (OAD monotherapy plus placebo), or active comparator (rosiglitazone or glimepiride).
Report a problemFND-1949153505
05HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on metformin monotherapy, minor hyperglycemia (as written in the abstract) was higher with glimepiride than with liraglutide.
In plain wordsIn adults with type 2 diabetes on metformin, minor blood sugar events were more frequent with glimepiride than with liraglutide.
Peptide
Liraglutide
Outcome
DecreaseMinor hyperglycemia rate on metformin monotherapy
Study
n: not reported in source
Comparator
Glimepiride
Analysis
Secondary
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.8 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
For patients on metformin monotherapy, the addition of liraglutide or glimepiride resulted in similar levels of glycemic control; however, patients receiving glimepiride had significantly greater weight gain (P < 0.0001) and higher rates of minor hyperglycemia.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis included a subset of patients receiving prior OAD monotherapy from 2 phase 3, 26-week, randomized, double-blind, double-dummy, active-control, parallel-group, multicenter, multinational trials.
Summary · context
Patients were then randomized to liraglutide (1.8 mg, 1.2 mg, or 0.6 mg once daily), placebo (OAD monotherapy plus placebo), or active comparator (rosiglitazone or glimepiride).
Report a problemFND-1949153506
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin monotherapy, adding liraglutide or glimepiride gave similar glycemic control.
In plain wordsIn adults with type 2 diabetes on metformin, adding liraglutide or glimepiride controlled blood sugar to a similar degree.
Peptide
Liraglutide
Outcome
No significant changeGlycemic control on metformin monotherapy
Study
n: not reported in source
Comparator
Glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
For patients on metformin monotherapy, the addition of liraglutide or glimepiride resulted in similar levels of glycemic control; however, patients receiving glimepiride had significantly greater weight gain (P < 0.0001) and higher rates of minor hyperglycemia.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis included a subset of patients receiving prior OAD monotherapy from 2 phase 3, 26-week, randomized, double-blind, double-dummy, active-control, parallel-group, multicenter, multinational trials.
Summary · context
Patients were then randomized to liraglutide (1.8 mg, 1.2 mg, or 0.6 mg once daily), placebo (OAD monotherapy plus placebo), or active comparator (rosiglitazone or glimepiride).
Report a problemFND-1949153504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT00318422

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 1,041May 2006 to May 2007

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 25 Jan 2017

CompletedPhase 3Results postedNCT00318461

To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together

Novo Nordisk A/Sn = 1,091May 2006 to Nov 2008

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 7 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.